Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Michael D. Farwell"'
Autor:
Robert H. Mach, Amy Ziober, Elizabeth S. McDonald, Anthony J. Young, Robert K. Doot, Daniel A. Pryma, Angela DeMichele, Sean D. Carlin, David A. Mankoff, Anupma Nayak, Erin K. Schubert, Payal D. Shah, Julia Tchou, Michael Feldman, Hsiaoju Lee, Amy S. Clark, Michael D. Farwell
Publikováno v:
Journal of Nuclear Medicine. 61:665-670
The σ2 receptor is a potential in vivo target for measuring proliferative status in cancer. The feasibility of using N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide (18F-ISO-1) to image solid tumor
Autor:
James J. Harding, Martha Ziolkowska, William Le, Jason S. Lewis, Jedd D. Wolchok, Neeta Pandit-Taskar, Michael S. Gordon, Ian D. Wilson, Christopher A. Barker, Anna M. Wu, Ron Korn, Frank Tsai, Michael D. Farwell, Deepak Behera, Tara C. Mitchell, Serge K. Lyashchenko, Joseph A. O'Donoghue, Michael A. Postow, Shutian Ruan, Wolfgang A. Weber, Matthew D. Hellmann
Publikováno v:
Journal of Nuclear Medicine. 61:512-519
Immunotherapy is becoming the mainstay for treatment of a variety of malignancies, but only a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T lymphocytes play a central role in antitumor immune responses. Noninvasiv
Autor:
Payal D. Shah, Daniel A. Pryma, Austin R. Pantel, Sean Carlin, Robert K. Doot, Michael D. Farwell, Elizabeth S. McDonald, Amy S. Clark
Publikováno v:
JCI Insight
JCI Insight, Vol 6, Iss 8 (2021)
JCI Insight, Vol 6, Iss 8 (2021)
BACKGROUND [18F]FluorThanatrace ([18F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that enables noninvasive quantification of PARP with potential to serve as a biomarker for patient selection for PARPi thera
Autor:
Jeffrey E. Gershenwald, Michael T. Tetzlaff, Peter A. Prieto, Jennifer L. McQuade, Charlotte E. Ariyan, Jonathan S. Zager, David F. McDermott, Adil Daud, Christian U. Blank, Kim Margolin, Richard A. Scolyer, Brett W. Carter, Elizabeth M. Burton, Richard D. Carvajal, Jeffrey A. Sosman, Alexander N. Shoushtari, April K.S. Salama, Scott E. Woodman, Tina J. Hieken, Vernon K. Sondak, Douglas S. Tyler, Jeffrey E. Lee, Frances C. Wright, Omid Hamid, David E. Fisher, Tanja D. de Gruijl, Miles C. Andrews, Michael C. Lowe, John M. Kirkwood, Keith T. Flaherty, Mark B. Faries, Grant A. McArthur, Dirk Schadendorf, Alexander C.J. van Akkooi, Alberto Fusi, Bart A. van de Wiel, James Larkin, Ken K. Tanabe, Jane L. Messina, Jennifer A. Wargo, Rodabe N. Amaria, Jonathan Cohen, Shaneen Sandhu, Andrew J. Spillane, Reinhard Dummer, Robert Antdbacka, Michael A. Postow, Michael D. Farwell, Céleste Lebbé, Jason J. Luke, Genevieve M. Boland, Tara C. Mitchell, David H. Lawson, Elisa A. Rozeman, Diwakar Davar, Caroline Robert, Kathryn Bollin, Ryan J. Sullivan, Michael A. Davies, Matteo S. Carlino, Isabella C. Glitza, Robyn P. M. Saw, Merrick I. Ross, Axel Hauschild, Teresa M. Petrella, Paolo A. Ascierto, Serigne Lo, Igor Puzanov, Samra Turajlic, Angela Hong, Roland L. Bassett, Keith A. Delman, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Susan M. Swetter, Janis M. Taube, Alexander M.M. Eggermont, John F. Thompson, Donald A. Berry, Leslie A. Fecher, Matthew S. Block, Alexander M. Menzies, David E. Gyorki, Helen Rizos
Publikováno v:
The Lancet Oncology. 20:e378-e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of
Publikováno v:
Nuclear Medicine Communications. 40:727-733
OBJECTIVE Determine the prevalence of benign indium-111 (In) pentetreotide uptake in the pancreatic head and determine if a semi-quantitative method can be used to differentiate physiologic from pathologic uptake. PATIENTS AND METHODS Institutional R
Autor:
Felix Quagliarello, Michael D. Farwell, Lydia Giles, Lakshmi Chilukuri, Qing Zhao, Sangeeth M. George, Melanie W. Kier, Shujing Liu, Patrick Yan, Lakshmanan Annamalai, Kurt D'Andrea, Suzanne McGettigan, Kristin Kreider, Wendy M. Blumenschein, Lynn M. Schuchter, Andrew Kozlov, Robin Mogg, Robert J. Orlowski, E. John Wherry, Bradley Wubbenhorst, Bertram Bengsch, Katherine L. Nathanson, Jennifer H. Yearley, Rosemarie Mick, Sasikanth Manne, Ramin S. Herati, Xiaowei Xu, Brandon Wenz, Tara C. Mitchell, Gerald P. Linette, Liza Dorfman, Alexander C. Huang, Adam A. Kraya, Ravi K. Amaravadi, Giorgos C. Karakousis, Wei Xu, Mary Carberry
Publikováno v:
Nature Medicine. 25:454-461
Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvir
Autor:
Michael D. Farwell, Wei-Ting Hwang, David L. Porter, Noelle V. Frey, Sarah J. Nagle, Carl H. June, Sunita D. Nasta, Jakub Svoboda, Nirav N. Shah, Drew A. Torigian, Daniel J. Landsburg, Stephen J. Schuster, Anthony R. Mato
Publikováno v:
Cytotherapy. 20:1415-1418
Molecular imaging with 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is an established modality for response assessment in patients with lymphoma undergoing treatment. However, patients treated with novel immuno
Autor:
Stephen M. Hahn, Mark H. O'Hara, Josh Bauml, Abigail T. Berman, John N. Lukens, Naomi B. Haas, Andy J. Minn, Tara C. Mitchell, Amit Maity, Michael D. Farwell, Robert H. Vonderheide, Dana Patsch, Angela DeMichele, Alexander C. Huang, Sangeeth M. George, Lynn M. Schuchter, E. John Wherry, Rosemarie Mick, John P. Christodouleas, Lilie L. Lin
Publikováno v:
British Journal of Cancer
We conducted a phase I trial evaluating pembrolizumab+hypofractionated radiotherapy (HFRT) for patients with metastatic cancers. There were two strata (12 patients each): (i) NSCLC/melanoma progressing on prior anti-PD-1 therapy, (ii) other cancer ty
Autor:
Roger A. Greenberg, Austin R. Pantel, Hyoung Kim, Robert K. Doot, David A. Mankoff, Lauren E. Schwartz, Chia-Ju Hsieh, Mehran Makvandi, Kuiying Xu, Catherine Hou, Daniel A. Pryma, Fiona Simpkins, Michael D. Farwell, Chi-Chang Weng, Harrison D. Winters, Lilie L. Lin, Robert H. Mach, Erin K. Schubert
Publikováno v:
Journal of Clinical Investigation. 128:2116-2126
BACKGROUND. Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in a broad population of patients with ovarian cancer; however, resistance caused by low enzyme expression of the drug target PARP-1 remains to be clinically evaluated in this co
Autor:
Michael D. Farwell, Yin Jie Chen
Publikováno v:
Clinical Nuclear Medicine. 43:864-866
Neuroendocrine tumors have a propensity to metastasize, but rarely to the orbits. A 69-year-old woman with history of neuroendocrine tumor of pancreatic primary underwent routine follow-up In-pentetreotide (OctreoScan) imaging, with 24-hour whole-bod